Garwood Medical Devices

Garwood Medical Devices is an early-stage, pre-revenue medical device company tackling the significant clinical and economic challenge of periprosthetic joint infections (PJIs). The company's proprietary platform technology, developed in partnership with the University at Buffalo, uses electrochemical methods to disrupt bacterial biofilms on implants, aiming to improve the success rate of early intervention treatments. With FDA Breakthrough Device designation for its BioPrax™ system, Garwood is positioned to address a high-cost, high-mortality unmet need in orthopedics, though it faces the typical risks of clinical development, regulatory hurdles, and market adoption for a novel therapeutic approach.

Proprietary platform using low-voltage electrochemical disruption to target and eliminate bacterial biofilms on metal medical implants.

Competes against the entrenched standard of care: surgical revision and antibiotic-loaded spacers. Also faces emerging competition from other novel biofilm-disrupting technologies, antimicrobial coatings for implants, and advanced local antibiotic delivery systems. The landscape is evolving but dominated by large orthopedic companies.